SecBot SecBot
SECBOTREPLAY Home › Report › RPRX

RPRX · Royalty Pharma is providing $250 million in non-dilutive,…

Royalty Pharma plc · PRESS-RELEASE filed Mar 2, 2026 at 06:10 ET

At the news

NEUTRALIMPACT 5/10

PRESS-RELEASE filed Mar 2, 2026 at 06:10 ET

Royalty Pharma is providing $250 million in non-dilutive, royalty-backed financing to Zymeworks, securing 30% of global tiered royalties from Ziihera® (zanidatamab) sales until repayment is complete. Zymeworks retains 70% of royalties and full rights post-repayment, using the capital for share repurchases, strategic acquisitions, and extending its cash runway beyond 2028.

  • Royalty Pharma is funding $250 million to Zymeworks via a non-recourse royalty-backed note.
  • Repayment will come from 30% of worldwide tiered royalties on Ziihera sales; Royalty Pharma receives up to 1.65x–1.925x the note amount depending on timing.
  • Zymeworks retains 70% of royalties during repayment and full rights thereafter.
  • Proceeds will support Zymeworks' stock buybacks, potential acquisitions, and cash runway beyond 2028.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access